ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,281.55
0.53%
Dow Jones
39,411.21
0.67%
Gold vs US Dollar
2,326.395
-0.19%
Brent Oil
85.235
-0.04%
Bitcoin
61,003.33
1.21%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Qualigen Therapeutics Inc (QLGN) Share Price

QLGN Qualigen Therapeutics Inc

0.1872
-0.0228 (-10.86%)
25 Jun 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Qualigen Therapeutics Inc NASDAQ:QLGN NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.0228 -10.86 0.1872 0.188 0.1925 0.2199 0.1881 0.2099 3,035,046 23:59:51   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -13.42M -2.1272 -0.21 2.84M
 Type  Size  Price  Time  Units 
 20 4,000 0.1872 23:59:50 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore QLGN News
30/05/202421:00EDGAR2Form 8-K - Current report
30/05/202421:00GLOBEQualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
14/05/202421:05EDGAR2Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
04/05/202401:59EDGAR2Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
16/04/202412:00GLOBEMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
10/04/202413:00GLOBEQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
09/04/202413:00GLOBEQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Period
Draw mode
Data Downloads for QLGN

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Qualigen Therapeutics Inc Articles